BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8473090)

  • 1. Bilateral orchiectomy in the management of stage D-2 prostate cancer.
    Guinan P; Firfer R; Targonski P; Rubenstein M
    Int Surg; 1993; 78(1):73-5. PubMed ID: 8473090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.
    Boel K; Van Poppel H; Goethuys H; Derluyn J; Vandenbroucke F; Popelier G; Casselman J; Billiet I; Vanuytsel L; Paridaens R; Baert L
    Anticancer Res; 1999; 19(3B):2157-61. PubMed ID: 10472324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment results of combined hormone and chemotherapy in patients with advanced prostate cancer].
    Uekado Y
    Hinyokika Kiyo; 1991 Aug; 37(8):825-31. PubMed ID: 1957724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer.
    Kubota Y; Nakada T; Suzuki Y; Iizima Y; Adachi Y; Hashimoto T
    Int Urol Nephrol; 1993; 25(5):469-74. PubMed ID: 8270375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.
    Granfors T; Modig H; Damber JE; Tomic R
    J Urol; 2006 Aug; 176(2):544-7. PubMed ID: 16813885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Retrospective clinical evaluation of prognosis factors in stage D2 prostatic cancer treated with endocrine therapy].
    Kudo K; Nagata M; Hayashi N; Imamura H; Kimura M; Mimura H; Matsuyama K; Shishido S; Chino I
    Hinyokika Kiyo; 1991 Feb; 37(2):129-34. PubMed ID: 1710871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormonal treatment of carcinoma of the prostate].
    Obata K; Kobayashi H; Murase T; Ohisi M
    Hinyokika Kiyo; 1991 Aug; 37(8):809-16. PubMed ID: 1720272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone therapy for locally advanced prostate cancer.
    Fowler JE; Bigler SA; White PC; Duncan WL
    J Urol; 2002 Aug; 168(2):546-9. PubMed ID: 12131306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison.
    Ghavamian R; Bergstralh EJ; Blute ML; Slezak J; Zincke H
    J Urol; 1999 Apr; 161(4):1223-7; discussion 1227-8. PubMed ID: 10081874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M; Carlström K; Rozell BL; Stege R; Pousette A
    Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
    Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
    J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
    Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
    Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of patients with clinical stage C prostate cancer treated by phototherapy and early orchiectomy. A retrospective analysis of 169 cases.
    Wiegel T; Tepel J; Schmidt R; Klosterhalfen H; Arps H; Berger P; Franke HD
    Strahlenther Onkol; 1996 Nov; 172(11):596-603. PubMed ID: 8946031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
    Zhang XZ; Donovan MP; Williams BT; Mohler JL
    Urology; 1996 Mar; 47(3):402-4. PubMed ID: 8633409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
    Halabi S; Vogelzang NJ; Ou SS; Small EJ
    J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
    Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
    J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.